M

    MoonLake Immunotherapeutics (MLTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.05
    +0.06 (+0.40%)

    Market Cap: $1.28B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(10/18)
    Avg Surprise
    +1.02%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.78
    Range$-0.86 - $-0.66
    4 analysts
    EPS Revisions
    1
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-1.03-31.7%
    60d ago$-0.94-21.1%
    30d ago$-0.92-18.5%
    7d ago$-0.91-16.4%
    Current$-0.78
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.76
    Range$-1.00 - $-0.34
    6 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.76---
    Sep 26EST
    		-$-0.78---
    Jun 26
    		$-0.84$-0.90+6.67%Beat+3.4%
    Mar 26
    		$-0.98$-0.92-6.52%Miss-55.6%
    Dec 25
    		$-0.92$-0.98+6.05%Beat-27.8%
    Sep 25
    		$-1.10$-0.89-23.60%Miss-96.4%
    Jun 25
    		$-0.87$-0.76-14.47%Miss-123.1%
    Mar 25
    		$-0.63$-0.74+14.34%Beat-186.4%
    Dec 24
    		$-0.72$-0.59-22.03%Miss-500.0%
    Sep 24
    		$-0.56$-0.45-24.44%Miss-211.1%
    Jun 24
    		$-0.39$-0.28-39.29%Miss-69.6%
    Mar 24
    		$-0.22$-0.21-4.76%Miss+4.3%
    Dec 23
    		$-0.12$-0.23+47.83%Beat+72.1%
    Sep 23
    		$-0.18$-0.25+28.00%Beat+33.3%
    Jun 23
    		$-0.23$-0.29+20.69%Beat+32.4%
    Mar 23
    		$-0.23$-0.31+25.81%Beat+34.3%
    Dec 22
    		$-0.43$-0.28-53.57%Miss-186.7%
    Sep 22
    		$-0.27$-0.34+20.59%Beat-92.9%
    Jun 22
    		$-0.34$-0.54+37.04%Beat-3300.0%
    Mar 22
    		$-0.35$-0.35+0.00%Beat-3400.0%
    Dec 21
    		$-0.15N/AN/ABeat-1400.0%
    Sep 21
    		$-0.14N/AN/ABeat-
    Jun 21
    		$-0.01N/AN/ABeat-
    Mar 21
    		$-0.01N/AN/ABeat-
    Dec 20
    		$-0.01N/AN/ABeat-
    Sep 20
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-3.92EV/EBITDA-41.53x
    Price/FCF-9.88xFCF Yield-10.12%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-67.50%ROIC-48.14%
    Financial Health
    Debt/Equity0.23xInterest Coverage-25.17x
    Current Ratio12.56xQuick Ratio12.56x
    Trading Statistics
    Beta1.07Avg Volume1.36M
    52-Week High$62.7552-Week Low$5.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.68
    SMA 20$16.45
    SMA 50$18.28
    SMA 200$16.86
    EMA 10$15.68
    EMA 20$16.37
    EMA 50$17.44
    EMA 200$20.10

    MACD

    Line: -0.88Signal: -0.80Hist: -0.08

    ADX

    ADX: 29.4+DI: 10.5-DI: 29.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$15.77

    Bollinger Bands

    Upper Band$18.46
    Lower Band$14.45
    %B Position2436%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    33.4

    Momentum Oscillators

    Stoch %K8.8
    Stoch %D9.3
    Williams %R-86.5
    ROC (10d)-8.0%
    Momentum-1.30
    CCI (20d)-133.8
    MFI (14d)37.3

    Volatility Measures

    ATR (14d)$0.76(5.1%)
    StdDev (20d)1.00
    Hist Vol43.8%(High)

    Volume Flow

    VWAP$14.93
    OBV53.7M
    AD Line3.6M
    CMF (20d)-0.038

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.7x
    VWMA (20d)$16.55

    Pivot Points

    R3$16.32
    R2$16.04
    R1$15.52
    Pivot Point$15.24
    S1$14.71
    S2$14.44
    S3$13.91

    Advanced Oscillators

    TSI-26.74
    Ultimate Osc37.2
    KST-158.15

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$101,850$0$0$0$19,738$0
    Cost of Revenue$0$0$751,000$0$0$0$50,925$0$0$0$3,289$0
    Gross Profit$0$0$-751,000$0$0$0$50,925$0$0$0$16,449$0
    Operating Expenses$61.66M$70.02M$65.22M$71.43M$60.70M$47.48M$49.58M$43.11M$30.58M$19.82M$15.03M$12.98M
    R&D$50.22M$54.52M$56.01M$60.63M$49.76M$36.46M$40.36M$35.74M$23.66M$13.01M$8.10M$7.59M
    SG&A$11.44M$15.51M$9.21M$10.80M$10.94M$11.03M$9.22M$7.38M$6.92M$6.81M$6.93M$5.39M
    Operating Income$-61,660,000$-70,024,000$-65,217,000$-71,434,000$-60,698,000$-47,485,000$-49,581,000$-43,112,000$-30,578,000$-19,820,000$-15,028,801$-12,976,743
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.63M$2.27M$2.00M$3.20M$2.04M$18,000$0$0$0$0$0$0
    Income Before Tax$-61,715,000$-69,085,000$-62,769,000$-70,579,000$-55,956,000$-40,406,000$-46,355,000$-36,022,000$-24,680,000$-13,905,000$-7,843,355$-11,590,430
    Income Tax Expense$90,000$622,000$248,000$115,000$95,000$153,000$41,000$92,000$79,000$70,000$43,918$28,923
    Net Income$-61,805,000$-69,707,000$-63,017,000$-70,694,000$-56,051,000$-40,559,000$-46,396,000$-36,114,000$-24,759,000$-13,975,000$-7,887,273$-11,619,353
    EBITDA$-58,187,000$-65,971,000$-60,023,000$-66,636,000$-53,177,000$-40,010,000$-45,991,000$-35,671,000$-24,338,000$-13,577,000$-7,483,224$-11,587,140
    EBIT$-59,083,000$-66,816,000$-60,774,000$-67,381,000$-53,919,000$-40,388,000$-46,355,000$-36,022,000$-24,680,000$-13,905,000$-7,843,355$-11,590,430
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MLTX

    News

    Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake

    Cormorant Asset Management, LP and Bihua Chen have disclosed a 4.35% beneficial ownership stake in MoonLake Immunotherapeutics (MLTX), totaling 3,205,433 Class A ordinary shares. This stake, reported via a SCHEDULE 13G/A filing, indicates shared voting and dispositive power over the shares and is based on 73,615,396 Class A ordinary shares outstanding as of May 1, 2026. The filing emphasizes that this ownership is less than 5% and is not intended to influence control of the issuer.

    Stock Titan•8/14/26•
    Neutral

    Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

    Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares, representing a 9.74% stake in MoonLake Immunotherapeutics (MLTX). This ownership includes 1,000,000 Pre-Funded Warrants, subject to a 9.99% "Maximum Percentage" exercise limitation. All reported shares are held with shared voting and dispositive power.

    Stock Titan•8/14/26•
    Neutral

    MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

    MoonLake Immunotherapeutics announced positive Week 16 topline results from its Phase 3 IZAR-1 trial for sonelokimab in biologic-naïve adults with active psoriatic arthritis, meeting all primary and secondary clinical endpoints. Despite the positive results, the stock fell over 6%. The company also reported strong financial standing with $537.0 million in cash, expected to fund operations into mid-2028, with full trial results anticipated in the first half of 2027.

    Sahm•8/12/26•
    Somewhat-Bearish

    Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO ( MLTX ) : Can the Stock Really Move This High?

    The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Zacks Commentary•7/31/26•
    Somewhat-Bullish

    Jerucon plans 150,000-share MLTX sale in Form 144 (Nasdaq: MLTX)

    Jerucon Beratungsgesellschaft mbH has filed a Form 144 notice to sell 150,000 Class A Ordinary shares of MoonLake Immunotherapeutics (MLTX) through UBS Financial Services, Inc. on or after July 15, 2026, for an aggregate value of $2,916,000. This filing also reports previous sales by Jerucon of 50,000 common shares on three separate days in June 2026, totaling over $2.8 million. The document provides details on the proposed sale and relevant SEC filing information.

    Stock Titan•7/15/26•
    Neutral

    Frequently Asked Questions About MLTX

    Does MLTX pay dividends?
    MoonLake Immunotherapeutics (MLTX) does not currently pay a regular dividend.
    What is MLTX's market cap?
    MoonLake Immunotherapeutics (MLTX) has a market capitalization of $1.28B with a current stock price of $15.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In